Recent Comments

Comment RSS

Bronchitis News and Research RSS Feed - Bronchitis News and Research

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

Scientists explore various imaging techniques to gain new insight into lung disease

21. November 2009 00:26
Chronic obstructive pulmonary disease (COPD), a respiratory disease commonly known as chronic bronchitis or emphysema, is the fourth leading cause of death worldwide. 600 million people live with COPD and while researchers have yet to find any real treatment or cure, Grace Parraga of Robarts Research Institute at The University of Western Ontario in London, Canada, is using various imaging techniques to gain new insight into the disease. [More]

Posted in: Medical Condition News

Tags: , , , , ,

New research studies seek to improve diagnosis and treatment for emphysema and other lung diseases

20. November 2009 01:01
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants. [More]

Posted in: Medical Condition News | Healthcare News

Tags: , , , , ,

Canadian comedian helps raise awareness about COPD

18. November 2009 07:32
COPD is no joke to Canadian comedian Mary Walsh. "It's shocking that so few Canadians know about COPD considering it's the fourth leading cause of death in this country," says Mary Walsh, spokesperson for The Canadian Lung Association. [More]

Posted in: Medical Condition News

Tags: , , , , ,

CHANTIX/CHAMPIX raises hope for quitting smoking

5. November 2009 01:50
New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP). [More]

USC: Heavy traffic corridors responsible for preventable childhood asthma

5. November 2009 01:37
Heavy traffic corridors in the cities of Long Beach and Riverside are responsible for a significant proportion of preventable childhood asthma, and the true impact of air pollution and ship emissions on the disease has likely been underestimated, according to researchers at the University of Southern California (USC). [More]

Posted in: Child Health News | Medical Condition News

Tags: , ,

NHLBI survey results reveal COPD awareness continues to grow in the United States

3. November 2009 01:05
Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. [More]

Posted in: Medical Condition News

Tags: , , , , , , , ,

3M launches new Rapid Detection Respiratory Syncytial Virus Test

28. October 2009 06:00
Expanding its platform of rapid diagnostic testing, 3M today announced the introduction of the 3M™ Rapid Detection RSV Test. RSV, or respiratory syncytial virus, is a respiratory virus that infects the lungs and breathing passages and is a common cause of bronchitis and pneumonia in children under one year. [More]

Posted in: Child Health News | Device / Technology News

Tags: , , , , , , , ,

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

27. October 2009 03:09
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. [More]

Sosei Group announces Phase III trials update on NVA237 and QVA149

22. October 2009 04:21
Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announces that the Phase III trials with NVA237, which commenced in June 2009, are proceeding to plan. Initiation of Phase III studies with QVA149 is now expected to occur during 2010. [More]

Posted in: Drug Trial News

Tags: ,

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

20. October 2009 05:35
Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA). [More]

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

19. October 2009 23:55
UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks. [More]

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

19. October 2009 09:41
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting. [More]

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

19. October 2009 07:43
Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent). [More]

Elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws: IOM

19. October 2009 04:34
A landmark report released today by the Institute of Medicine provides powerful new evidence that elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws. The IOM report concludes smoke-free laws reduce the number of heart attacks and save lives. The report also confirms that there is conclusive scientific evidence that secondhand smoke causes heart disease, including heart attacks, and finds there is compelling evidence that even relatively brief exposure to secondhand smoke can lead to a heart attack. [More]

Posted in: Medical Condition News | Miscellaneous News

Tags: , , , , , , ,

Report on inhaled pharmaceutical therapy developers

6. October 2009 00:22
Research and Markets (http://www.researchandmarkets.com/research/e40af4/the_top_40_develop) has announced the addition of the "The Top 40 Developers Of Inhaled Pharmaceuticals Worldwide" report to their offering. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.